Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 132   

Articles published

JNJ 98.96 +0.21 (0.21%)
price chart
Johnson & Johnson Profit Jumps As Prescription Drug Sales Surge And Outlook ...
Johnson & Johnson, the maker of medicines like Tylenol and consumer products like Aveeno and Listerine, reported $18.1 billion in first quarter revenue, beating Street estimates of $17.99 billion and coming in 3.5% above the $17.5 billion reported for ...
Johnson & Johnson Earnings: Will Tuesday Bring More Good News for J&J?  Motley Fool
My Top Company For Income And Capital Gains  Seeking Alpha
Related articles »  
Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Investors focusing on Johnson and Johnson's (NYSE: JNJ ) 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed.
Sales of Johnson & Johnson's New Hepatitis C Drug Soar  Wall Street Journal
Johnson & Johnson Stock Attractive as It Raises Forecast  Barron's
Related articles »  
Johnson & Johnson's 3 Major Strengths
I recently wrote a mini-series on Johnson & Johnson (NYSE: JNJ ) , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices.
Why Coca-Cola and Johnson & Johnson Will Move the Dow Tomorrow
Johnson & Johnson has scheduled a conference call for 8:30 a.m. EDT following the release of its earnings report, which could come around 7:45 a.m.
Stocks to Watch: Coca-Cola, Johnson & Johnson, Zebra Technologies  Wall Street Journal (blog)
Jim Cramer: Why Johnson & Johnson (JNJ) and Coca-Cola (KO) Reported ...  TheStreet.com
Related articles »  
J&J beats forecasts, as it marches toward specialty care
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
Johnson & Johnson earnings jump, beat Street  USA TODAY
Related articles »  
Arkansas Court Reverses $1.2 Billion Judgment Against Johnson & Johnson
The Arkansas Supreme Court reversed a $1.2 billion judgment against Johnson & Johnson on Thursday, finding that the state attorney general erred by suing under a law that applied to health care facilities, not drug companies.
Arkansas court throws out $1.2 billion Risperdal judgment against Johnson ...  Dallas Morning News
Related articles »  
Is Johnson & Johnson's Dividend Unbeatable?
Major health-care stocks out of big pharma and medical devices offer great dividends, but few offer the strength and reliability of sector colossus Johnson & Johnson (NYSE: JNJ ) . While it may not boast the highest yield in health care at only 2.7 ...
Johnson & Johnson: The Right Treatment
Johnson & Johnson (NYSE: JNJ) is one of America's most established companies. It traces its roots back 128 years, to 1886, when it was founded by three brothers: Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson, in New Brunswick, ...
Dow Today: Johnson & Johnson (JNJ) Lower
Holding back the Dow today is Johnson & Johnson (NYSE:JNJ), which is lagging the broader Dow index with a 51-cent decline (-0.5%) bringing the stock to $98.69.
Does Johnson & Johnson Belong in Your Portfolio?
With shares of Johnson & Johnson (NYSE:JNJ) trading around $98, is JNJ an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework: ...
Related articles »